INmune Bio Net Income
| INMB Stock | USD 1.51 0.09 6.34% |
As of the 8th of February, INmune Bio retains the Market Risk Adjusted Performance of (0.09), standard deviation of 4.66, and Risk Adjusted Performance of (0.02). INmune Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
INmune Bio Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 264.4777 | Revenue | Earnings Share (2.08) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -37.9 M | -36 M | |
| Net Loss | -24.6 M | -23.3 M | |
| Net Loss | -37.9 M | -36 M | |
| Net Loss | (2.43) | (2.31) |
INmune | Net Income | Build AI portfolio with INmune Stock |
Analyzing INmune Bio's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing INmune Bio's current valuation and future prospects.
Latest INmune Bio's Net Income Growth Pattern
Below is the plot of the Net Income of INmune Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in INmune Bio financial statement analysis. It represents the amount of money remaining after all of INmune Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is INmune Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in INmune Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (42.08 M) | 10 Years Trend |
|
Net Income |
| Timeline |
INmune Net Income Regression Statistics
| Arithmetic Mean | (14,032,330) | |
| Coefficient Of Variation | (114.84) | |
| Mean Deviation | 14,204,345 | |
| Median | (7,678,313) | |
| Standard Deviation | 16,114,840 | |
| Sample Variance | 259.7T | |
| Range | 42M | |
| R-Value | (0.91) | |
| Mean Square Error | 45.6T | |
| R-Squared | 0.84 | |
| Slope | (2,916,609) | |
| Total Sum of Squares | 4155T |
INmune Net Income History
Other Fundumenentals of INmune Bio
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
INmune Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for INmune Bio is extremely important. It helps to project a fair market value of INmune Stock properly, considering its historical fundamentals such as Net Income. Since INmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of INmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of INmune Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
INmune Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to INmune Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of INmune Bio.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in INmune Bio on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding INmune Bio or generate 0.0% return on investment in INmune Bio over 90 days. INmune Bio is related to or competes with CEL SCI, Barinthus Biotherapeutics, Aligos Therapeutics, Tempest Therapeutics, OnKure Therapeutics, Skye Bioscience, and X4 Pharmaceuticals. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate i... More
INmune Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure INmune Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess INmune Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 6.82 |
INmune Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for INmune Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as INmune Bio's standard deviation. In reality, there are many statistical measures that can use INmune Bio historical prices to predict the future INmune Bio's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.1) |
INmune Bio February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 3.69 | |||
| Coefficient Of Variation | (2,942) | |||
| Standard Deviation | 4.66 | |||
| Variance | 21.74 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.1) | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 6.82 | |||
| Skewness | 0.0554 | |||
| Kurtosis | (0.03) |
INmune Bio Backtested Returns
At this point, INmune Bio is very risky. INmune Bio holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for INmune Bio, which you can use to evaluate the volatility of the firm. Please check out INmune Bio's Standard Deviation of 4.66, risk adjusted performance of (0.02), and Market Risk Adjusted Performance of (0.09) to validate if the risk estimate we provide is consistent with the expected return of 0.0331%. The company retains a Market Volatility (i.e., Beta) of 1.76, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, INmune Bio will likely underperform. INmune Bio right now retains a risk of 4.64%. Please check out INmune Bio maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if INmune Bio will be following its current trending patterns.
Auto-correlation | 0.31 |
Below average predictability
INmune Bio has below average predictability. Overlapping area represents the amount of predictability between INmune Bio time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of INmune Bio price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current INmune Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
INmune Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, INmune Bio reported net income of (42.08 Million). This is 112.33% lower than that of the Biotechnology sector and 160.08% lower than that of the Health Care industry. The net income for all United States stocks is 107.37% higher than that of the company.
INmune Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.INmune Bio is currently under evaluation in net income category among its peers.
INmune Bio Institutional Holders
Institutional Holdings refers to the ownership stake in INmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of INmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing INmune Bio's value.| Shares | Simplex Trading, Llc | 2025-06-30 | 70.3 K | Bank Of New York Mellon Corp | 2025-06-30 | 61.6 K | Charles Schwab Investment Management Inc | 2025-06-30 | 51.8 K | Buckingham Strategic Partners | 2025-06-30 | 48.8 K | Royal Bank Of Canada | 2025-06-30 | 48.8 K | Mccormack Advisors International | 2025-06-30 | 48.2 K | Scientech Research Llc | 2025-06-30 | 45.7 K | Lpl Financial Corp | 2025-06-30 | 43.2 K | Millennium Management Llc | 2025-06-30 | 42.6 K | Blackrock Inc | 2025-06-30 | 1.2 M | Vanguard Group Inc | 2025-06-30 | 847.8 K |
INmune Fundamentals
| Return On Equity | -1.56 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (697.24) % | ||||
| Current Valuation | 13.22 M | ||||
| Shares Outstanding | 26.59 M | ||||
| Shares Owned By Insiders | 17.01 % | ||||
| Shares Owned By Institutions | 17.37 % | ||||
| Number Of Shares Shorted | 3.9 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 802.87 X | ||||
| Revenue | 14 K | ||||
| Gross Profit | 50 K | ||||
| EBITDA | (42.08 M) | ||||
| Net Income | (42.08 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 384 K | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 0.95 X | ||||
| Cash Flow From Operations | (33.36 M) | ||||
| Short Ratio | 10.70 X | ||||
| Earnings Per Share | (2.08) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 40.14 M | ||||
| Total Asset | 39.56 M | ||||
| Retained Earnings | (163.1 M) | ||||
| Working Capital | 15.44 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
| Net Asset | 39.56 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.